Evidence map›Paper›PMID 38735167›Full record

ArticleThrombosis research2024

Pulmonary vein thrombosis: Clinical presentation and outcomes.

Daniel Sykora, Robert A Churchill, David O Hodge, Steven Callori, Damon E Houghton, Robert D McBane, Waldemar E Wysokinski

Abstract read
In one paragraph

Article in Thrombosis research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel SykoraMayo Clinic, School of Graduate Medical Education, Rochester, MN, United States of America.
Robert A ChurchillMayo Clinic, Alix School of Medicine, Rochester, MN, United States of America.
David O HodgeMayo Clinic, Division of Clinical Trials and Biostatistics, Jacksonville, FL, United States of America.
Steven CalloriMayo Clinic, Alix School of Medicine, Rochester, MN, United States of America.
Damon E HoughtonMayo Clinic, Department of Cardiovascular Medicine, Rochester, MN, United States of America.
Robert D McBaneMayo Clinic, Department of Cardiovascular Medicine, Rochester, MN, United States of America.
Waldemar E WysokinskiMayo Clinic, Department of Cardiovascular Medicine, Rochester, MN, United States of America. Electronic address: wysokinski.waldemar@mayo.edu.

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

backgroundPulmonary vein thrombosis (PVT) is a rare thromboembolic disease with potential high-risk complications related to arterial embolization, but little is known regarding risk factors and outcomes.

objectiveTo describe the etiology, management, and clinical course of PVT.

methodsInstitutional health records were queried (1/1/2001-12/30/2023) to identify patients ≥18 years of age diagnosed with PVT. Thrombosis, bleeding, respiratory failure, and all-cause mortality were analyzed. Suspected tumor thrombus cases were excluded.

results72 patients with PVT were identified (median age 62 years, 50 % female), and PVT was overall rare at 3.1 diagnosed cases per year at our institution. PVT primarily affected a single vein (89 %), most commonly the left upper PV (40 %). Of these, 37 % occurred while on therapeutic anticoagulation. The most common risk factors included cancer (55 %) and related surgical lobectomy (21 %). Extrinsic vein compression (17 %) and recent surgery (19 %) were also common; 19 % were deemed idiopathic. Most patients (76 %) were treated with anticoagulation and frequently indefinite duration (80 %). During a median follow-up of 11.7 months (IQR 39.5 months), serial imaging (available for 68 %) revealed PVT resolution in 64 %. Four-year Kaplan-Meier probability of outcome included: left atrial thrombus (21 %), need for mechanical ventilation (14 %), pneumonia (9 %), and ischemic stroke (9 %). The mortality rate was 46 % with median survival 14 months after PVT diagnosis.

conclusionPVT is often associated with active malignancy, lobectomy, recent surgery, and extrinsic vein compression; 1 in 5 cases were idiopathic. Notable complications include left atrial thrombus with arterial embolism including stroke. With anticoagulation, most thrombi resolve over time. Mortality rates are high, reflecting the high the prevalence of cancer.

Indexed as

Pulmonary VeinsVenous ThrombosisAgedFemaleHumansMaleMiddle AgedRisk FactorsTreatment OutcomeCancerIschemic strokeLobectomyPulmonary vein thrombosisVenous thromboembolism

Identifiers

PMID38735167
PMCPMC11209840

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.